MICHELE WEBBER-KLEIN: Open Payments
NPI 1770660953 · FRESNO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$999 in 8 payments from 6 companies in 2025. Trend: 2023 $363 · 2024 $441 · 2025 $999
Food & beverage: $999
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 3 | $368 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $150 |
| Otsuka America Pharmaceutical, Inc. | 1 | $125 |
| Vanda Pharmaceuticals Inc. | 1 | $124 |
| Neurocrine BioSciences, Inc. | 1 | $117 |
| Biogen, Inc. | 1 | $114 |
Products named: UZEDY, CAPLYTA, REXULTI, FANAPT, AUSTEDO XR, INGREZZA, ZURZUVAE.
Industry payments across CA — which companies pay providers there.
